WELCOME AT BAYER BEE CARE

Bayer CropScience welcomes the proportionate response of Member States on EU Commission proposal on neonicotinoids

The company will continue to engage further in dialogue to support the safe use of neonicotinoid products

Bayer CropScience welcomes the fact that no consensus was reached by the EU Member States in favor of the European Commission’s proposals regarding the use of most applications of neonicotinoid-containing products. This provides hope to European farmers, that they can continue to have access to safe and effective crop protection products supporting their ability to grow safe, high-quality, affordable food. The failure to reach a conclusive decision is a clear recognition that there is no convincing argument against the continuing use of neonicotinoid-based products.

Bayer CropScience believes this response provides an opportunity to reach a fair and just outcome as the European Commission has relied too heavily on the precautionary principle, without taking the principle of proportionality into account. Not only had the Commission incorrectly based their rationale on recent EFSA reviews of these products, they had failed to make the appropriate impact assessments of any decisions they proposed on the broader interests of European stakeholders.

The company continues to believe that any political decision relating to registrations of neonicotinoid-containing products, should be based on clear, scientific evidence of adverse effects of the affected products under realistic conditions of use, including the extensive stewardship measures that are in place in the field. There has been a long history of the safe use of neonicotinoid insecticides and it is clear that when they are used responsibly and properly, any impact on bees is negligible. This has already been confirmed by the competent EU and Member State authorities in their market authorization assessments, based on the extensive safety data that had previously been submitted and proven in many monitoring studies.

As a responsible corporate citizen, Bayer CropScience is strongly committed to supporting the responsible use of neonicotinoids and will continue to engage further in dialogue with stakeholders, EU and Member States authorities.

About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. This year the company looks back on 150 years of working to fulfill its mission “Bayer: Science For A Better Life.” Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 8,383 million (2012) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 20,800 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.

Contact:
Julian Little, Tel. +44 1223-226606
E-Mail: julian.little@bayer.com

Utz Klages, Tel. +49 2173 38-3125
E-Mail: utz.klages@bayer.com

Find more information at www.bayercropscience.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Back To Top